VECTURA

 

VECTURA (VEC.L, LSE, LSE:VEC)

VEC Share PerformanceMore

52 week high183.75 12/06/15
52 week low113.25 16/10/14
52 week change 31.50 (21.28%)
4 week volume12,834,886 08/06/15

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Voting Rights and Capital

RNS Number: 7314R Vectura Group plc 01 July 2015 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 July 2015: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: The Compan...

TR-1 Notification of Major Interest in Shares

RNS Number: 3743R Vectura Group plc 26 June 2015 For filings with the FCA include the annex For filings with the issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Vectura Group Plc 2 Reason for the notification (please tick...

Why Vectura Group PLC Could Be The Perfect Partner For AstraZeneca plc In Your Portfolio

One of the most important aspects of investing is seeking out companies with clear catalysts for share price growth. Certain...

AstraZeneca man becomes CEO at Vectura

Vectura Group (LSE: VEC), which specialises in the development of products for the treatment of airways-related diseases...

Appoints James Ward-Lilley as CEO

RNS Number: 0033R Vectura Group plc 24 June 2015 Vectura Group plc Appoints James Ward-Lilley as CEO Chippenham, UK - 24 June 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), which specialises in the development of products for the treatment of airways-related diseases, announces the appointment of James Ward-Lilley as CEO and Exe...

Planned development of QVM149 for asthma

RNS Number: 4813Q Vectura Group plc 18 June 2015 Vectura Group plc Planned development of inhaled triple therapy QVM149 for asthma Chippenham, UK - 18 June 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), confirms Novartis today announced plans to develop a new inhaled dry powder triple therapy for patients with moderate to severe...

Director declaration

RNS Number: 2107Q Vectura Group plc 16 June 2015 Vectura Group plc Director declaration Chippenham, UK - 16 June 2015: In accordance with Listing Rule 9.6.14 (2) Vectura Group plc (LSE: VEC) announces that Neil Warner, Non-Executive Director of Vectura, has been appointed as Senior Independent Non-Executive Director of Trifast plc (LSE: TRI), with imm...

Annual Report and Accounts

RNS Number: 1783Q Vectura Group plc 15 June 2015 15 June 2015 Vectura Group plc Annual Report and Accounts 2015 In accordance with the Listing Rule 9.6.1, a copy of the following document has been submitted to the UK Listing Authority. - Annual Report and Accounts 2015. The document has been submitted to the National Storage Mechanism and will shortly...